SPECIALTY TOPICS · GUIDE
Skin and Cosmetic Peptides: GHK-Cu, Matrixyl and Argireline
An overview of skin-care peptides such as GHK-Cu, Matrixyl and Argireline: names versus molecules, what studies show, cosmetic versus drug claims, and what is unproven.
Content last updated . This page has not been medically reviewed.
Back to Peptides & Modern ResearchCosmetic peptides in brief
Many serums and creams list peptides on the label. Most are short chains of amino acids made by chemical synthesis or by partly digesting animal proteins. [1] One 2025 review counted 102 commercially available cosmetic peptides and found their supporting evidence ranges widely, mostly from laboratory and skin-sample (ex vivo) work. [2]This page is information only. It does not recommend products.
Names, brands and molecules are not the same thing
A label name can be a brand, a mixture or a standard ingredient name. They are related but not interchangeable.| Name you may see | What it is | Notes |
|---|---|---|
| Palmitoyl pentapeptide-4 | Standard cosmetic ingredient name (INCI) | The palmitoyl version of the five-amino-acid chain KTTKS. [3] |
| Matrixyl | Brand name | Described in one paper as the N-palmitoyl derivative of KTTKS. [3] Older papers sometimes call it "palmitoyl pentapeptide-3", so the number is not consistent across the literature. [4] |
| Matrixyl 3000 | Brand name for a blend | Contains palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, a different pair of molecules. [5] |
| Acetyl hexapeptide-8 | Standard ingredient name | Also known as Argireline. [6] |
| Argireline | Registered trademark | Used for acetyl hexapeptide-8 in the literature. [7] |
| GHK-Cu | Copper complex of the three-amino-acid peptide GHK | Pal-GHK is a separate, fatty-acid-modified form. [8] |
Ingredient names can also mislead. For example, the ingredient named "Tripeptide-10 Citrulline" is described in its own paper as a tetrapeptide. [9] The number in a name is not a reliable count of amino acids. See what are cosmetic peptides and the ingredient families.
Cosmetic versus drug claims
In the U.S., cosmetic products and ingredients (other than color additives) do not need FDA approval before sale. [10] The law does not recognize a category called "cosmeceuticals." [10] Certain claims can cause a product to be considered a drug even if it is sold as a cosmetic. [10] Laws differ in other countries and we did not verify them.What research shows, ingredient by ingredient
GHK-Cu and copper peptides. Cell studies support a role in skin repair, but a 2025 review noted a "surprising absence of clinical studies" on GHK-Cu and Pal-GHK. [8] A 2026 review called clinical evidence sparse and GHK-Cu "promising but unproven." [11] Label: preclinical, with insufficient evidence for wrinkles in people. See GHK-Cu.Matrixyl (palmitoyl pentapeptide-4). One small double-blind trial of 21 women compared two peptide creams and a placebo cream around the eyes for eight weeks. The authors called it an initial study needing more subjects and longer follow-up. [12] Label: promising but limited. See palmitoyl pentapeptide-4.
Argireline (acetyl hexapeptide-8). A 2025 review found the molecule is hydrophilic and fairly large, so it has limited ability to cross the skin's outer layer, and whether it reaches the nerve-muscle junction when applied to skin remains uncertain. [13] Calling it "botox-like" is a marketing claim; clinical studies suggest it may reduce wrinkle depth, but the mechanism on skin is incompletely understood. [13] See acetyl hexapeptide-8.
What the pooled evidence says
A 2026 meta-analysis of 19 randomized trials (1,341 people) of oral and topical peptides found a modest pooled effect on wrinkles, driven largely by oral products; effects on elasticity and density were inconsistent. [14] Because oral and topical products were combined, it cannot say whether any one serum works. A broader 2026 review of skin-aging products found small studies, short durations, subjective outcomes and frequent industry sponsorship across the field. [15]Frequently asked questions
Do copper peptides work for wrinkles?
Cell studies support a possible role, but a 2025 review found a surprising absence of clinical studies on GHK-Cu and Pal-GHK. [8]
Is Argireline the same as Botox?
No. Argireline is a trade name for acetyl hexapeptide-8, a cosmetic ingredient. [6] A 2025 review says it is uncertain whether it can reach nerve-muscle junctions when applied to skin. [13]
Are cosmetic peptides FDA approved?
Cosmetic ingredients generally do not require FDA approval before they are sold in the U.S. [10]
Is Matrixyl one molecule?
"Matrixyl" refers to the palmitoyl form of KTTKS, while "Matrixyl 3000" is a blend of two other palmitoylated peptides. [3] [5]
Are injectable GHK-Cu products safe?
The FDA says compounded injectable GHK-Cu may pose an immunogenicity risk and that human data on safety are limited. [17]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: promising but limited (a few small human studies), preclinical (cells or animals only), insufficient evidence, and marketing claim (said on a label or website without a study behind it).
Safety and how to judge a product
- Any cosmetic can irritate or cause an allergic reaction; this is general caution rather than a finding from a peptide trial.
- A label lists ingredients but not how much of each is present. Ingredients at one percent or less may be listed in any order. [16]
- Studies of a finished serum do not prove the peptide inside it works; see ingredient evidence versus finished-product evidence.
- Injectable "copper peptide" is a different matter from a cream. The FDA lists injectable GHK-Cu among withdrawn bulk-substance nominations, noting possible immune-reaction risk and limited human safety data. [17] See peptide safety.
- Ask a dermatologist about skin concerns; see also how to evaluate peptide claims.
References
- Skibska et al. Signal Peptides - Promising Ingredients in Cosmetics. Curr Protein Pept Sci 2021. Read 2026-10-22.
- Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence. Peptides 2025. Read 2026-10-22.
- Boosting cosmeceutical peptides: coupling imidazolium-based ionic liquids to pentapeptide-4 originates new leads. Microbiol Spectr 2022. Read 2026-10-22.
- The effects of a novel series of KTTKS analogues on cytotoxicity and proteolytic activity. Molecules 2019. Read 2026-10-22.
- Permeation behaviour of cosmetic actives into the human stratum corneum. Int J Pharm 2026. Read 2026-10-22.
- Public interest in acetyl hexapeptide-8: longitudinal analysis. JMIR Dermatol 2024. Read 2026-10-22.
- Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8. Clin Ter 2020. Read 2026-10-22.
- Mortazavi et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts 2025. Read 2026-10-22.
- A new decorin-like tetrapeptide for optimal organization of collagen fibres. Int J Cosmet Sci 2008. Read 2026-10-22.
- U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Read 2026-10-22.
- GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics 2026. Read 2026-10-22.
- Aruan et al. Double-blind, randomized trial on acetylhexapeptide-3 cream and palmitoyl pentapeptide-4 cream for crow's feet. J Clin Aesthet Dermatol 2023. Read 2026-10-22.
- Zdrada-Nowak et al. Acetyl hexapeptide-8 in cosmeceuticals: a review of skin permeability and efficacy. Int J Mol Sci 2025. Read 2026-10-22.
- Nukaly et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med 2026. Read 2026-10-22.
- Topical and systemic skin aging interventions: evidence, pitfalls and perspectives. Biochem Pharmacol 2026. Read 2026-10-22.
- U.S. Food and Drug Administration. Summary of Cosmetics Labeling Requirements. Read 2026-10-22.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). Read 2026-10-22.